These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38916823)

  • 1. Matching-Adjusted Indirect Comparison of the 52-Week Efficacy of Bimekizumab Versus Secukinumab and Ixekizumab for the Treatment of Radiographic Axial Spondyloarthritis.
    Maksymowych WP; Thom H; Mørup MF; Taieb V; Willems D; Lyris N; Gaffney K
    Rheumatol Ther; 2024 Aug; 11(4):1023-1041. PubMed ID: 38916823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost-effectiveness of a bimekizumab versus IL-17A inhibitors treatment-pathway in patients with active axial spondyloarthritis in Scotland.
    Mørup MF; Taieb V; Willems D; Rose M; Lyris N; Lamotte M; Gerlier L; Thom H
    J Med Econ; 2024; 27(1):682-696. PubMed ID: 38650583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison.
    Mease PJ; Warren RB; Nash P; Grouin JM; Lyris N; Willems D; Taieb V; Eells J; McInnes IB
    Rheumatol Ther; 2024 Jun; 11(3):817-828. PubMed ID: 38446397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials.
    van der Heijde D; Deodhar A; Baraliakos X; Brown MA; Dobashi H; Dougados M; Elewaut D; Ellis AM; Fleurinck C; Gaffney K; Gensler LS; Haroon N; Magrey M; Maksymowych WP; Marten A; Massow U; Oortgiesen M; Poddubnyy D; Rudwaleit M; Shepherd-Smith J; Tomita T; Van den Bosch F; Vaux T; Xu H
    Ann Rheum Dis; 2023 Apr; 82(4):515-526. PubMed ID: 36649967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy and safety of bimekizumab in axial spondyloarthritis: a systematic literature review and network meta-analysis.
    Deodhar A; Machado PM; Mørup M; Taieb V; Willems D; Orme M; Pritchett D; Gensler LS
    Rheumatology (Oxford); 2024 May; 63(5):1195-1205. PubMed ID: 37947318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ixekizumab improves spinal pain, function, fatigue, stiffness, and sleep in radiographic axial Spondyloarthritis: COAST-V/W 52-week results.
    Deodhar AA; Mease PJ; Rahman P; Navarro-Compán V; Strand V; Hunter T; Bolce R; Leon L; Lauzon S; Marzo-Ortega H
    BMC Rheumatol; 2021 Sep; 5(1):35. PubMed ID: 34538257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.
    van der Heijde D; Cheng-Chung Wei J; Dougados M; Mease P; Deodhar A; Maksymowych WP; Van den Bosch F; Sieper J; Tomita T; Landewé R; Zhao F; Krishnan E; Adams DH; Pangallo B; Carlier H;
    Lancet; 2018 Dec; 392(10163):2441-2451. PubMed ID: 30360964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of ixekizumab in non-radiographic axial spondyloarthritis.
    San Koo B; Kim TH
    Ther Adv Musculoskelet Dis; 2021; 13():1759720X20986734. PubMed ID: 33488787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison.
    Warren RB; McInnes IB; Nash P; Grouin JM; Lyris N; Willems D; Taieb V; Eells J; Mease PJ
    Rheumatol Ther; 2024 Jun; 11(3):829-839. PubMed ID: 38488975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis.
    Webers C; Ortolan A; Sepriano A; Falzon L; Baraliakos X; Landewé RBM; Ramiro S; van der Heijde D; Nikiphorou E
    Ann Rheum Dis; 2023 Jan; 82(1):130-141. PubMed ID: 36270657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial.
    Deodhar A; van der Heijde D; Gensler LS; Kim TH; Maksymowych WP; Østergaard M; Poddubnyy D; Marzo-Ortega H; Bessette L; Tomita T; Leung A; Hojnik M; Gallo G; Li X; Adams D; Carlier H; Sieper J;
    Lancet; 2020 Jan; 395(10217):53-64. PubMed ID: 31813637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Efficacy of Advanced Therapies in the Treatment of Radiographic Axial Spondyloarthritis or Ankylosing Spondylitis as Evaluated by the ASDAS Low Disease Activity Criteria.
    Baraliakos X; Saffore CD; Collins EB; Parikh B; Ye X; Walsh JA
    Rheumatol Ther; 2024 Aug; 11(4):989-999. PubMed ID: 38858318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Ixekizumab on Work Productivity in Patients with Ankylosing Spondylitis: Results from the COAST-V and COAST-W Trials at 52 Weeks.
    Marzo-Ortega H; Mease PJ; Rahman P; Navarro-Compán V; Strand V; Dougados M; Combe B; Wei JC; Baraliakos X; Hunter T; Sandoval D; Li X; Zhu B; Bessette L; Deodhar A
    Rheumatol Ther; 2020 Dec; 7(4):759-774. PubMed ID: 32814997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Efficacy of Biologic Disease-Modifying Anti-Rheumatic Drugs for Non-Radiographic Axial Spondyloarthritis: A Systematic Literature Review and Bucher Indirect Comparisons.
    Akkoç N; Arteaga CH; Auteri SE; Betts M; Fahrbach K; Kim M; Kiri S; Neupane B; Gaffney K; Mease PJ
    Rheumatol Ther; 2023 Apr; 10(2):307-327. PubMed ID: 36633815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ixekizumab for treating ankylosing spondylitis.
    Kiwalkar S; Beier S; Deodhar A
    Immunotherapy; 2019 Oct; 11(15):1273-1282. PubMed ID: 31530049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W).
    Dougados M; Wei JC; Landewé R; Sieper J; Baraliakos X; Van den Bosch F; Maksymowych WP; Ermann J; Walsh JA; Tomita T; Deodhar A; van der Heijde D; Li X; Zhao F; Bertram CC; Gallo G; Carlier H; Gensler LS;
    Ann Rheum Dis; 2020 Feb; 79(2):176-185. PubMed ID: 31685553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis.
    Mease P; Walsh JA; Baraliakos X; Inman R; de Vlam K; Wei JC; Hunter T; Gallo G; Sandoval D; Zhao F; Dong Y; Bolce R; Marzo-Ortega H
    Rheumatol Ther; 2019 Sep; 6(3):435-450. PubMed ID: 31254223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison.
    Mease PJ; Warren RB; Nash P; Grouin JM; Lyris N; Willems D; Taieb V; Eells J; McInnes IB
    Rheumatol Ther; 2024 Oct; 11(5):1403-1412. PubMed ID: 39120849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.